Geburtshilfe Frauenheilkd 2016; 76(10): 1086-1091
DOI: 10.1055/s-0042-105286
Original Article
GebFra Science
Georg Thieme Verlag KG Stuttgart · New York

Routine Treatment of Cervical Cytological Cell Changes

Diagnostic Standard, Prevention and Routine Treatment of Cervical Cytological Cell Changes – An Assessment of Primary and Secondary Prevention and Routine Treatment Data in the Context of an Anonymous Data Collection from Practicing Gynaecologists; an Academic, Non-Interventional StudyBehandlungsroutine bei zervikalen zytologischen ZellveränderungenDiagnostischer Standard, Prävention und Behandlungsroutine bei zervikalen zytologischen Zellveränderungen – Erfassung der primären und sekundären Prävention sowie Behandlungsroutine im Rahmen einer retrospektiven anonymisierten Datenerfassung bei niedergelassenen Gynäkologen, eine akademische, nicht interventionelle Studie
J. Huber
1   ANISNet Academic Non-Interventional Study Net
2   Specialist in Gynecology and Obstetrics, Vienna, Austria
,
B. Pötsch
3   Specialist in Gynecology and Obstetrics, Leibnitz, Austria
,
M. Gantschacher
4   Head of Department of Health Legislation and Health Science, and WHO Austrian Drug Monitoring Center, Sigmund Freud Private University, Vienna
5   Assistant Director of the ESQH Vienna Office, Vienna, Austria
,
M. Templ
6   Data-analysis OG, Vienna, Austria
› Author Affiliations
Further Information

Publication History

received 19 November 2015
revised 17 February 2016

accepted 20 March 2016

Publication Date:
14 October 2016 (online)

   Permissions and Reprints

Abstract

Introduction: Diagnosis and treatment of vaginal and cervical cytological cell changes are described in European and national guidelines. The aim of this data collection was to evaluate the remission rates of PAP III and PAP III D cytological findings in patients over a period of 3–4 months.

Method: The current state of affairs in managing suspicious and cytological findings (PAP III, and III D) in gynecological practice was assessed in the context of a data collection survey. An evaluation over a period of 24 months was conducted on preventative measures, the occurrence and changes to normal/suspect/pathological findings and therapy management (for suspicious or pathological findings).

Results: 307 female patients were included in the analysis. At the time of the survey 186 patients (60.6 %) had PAP III and 119 (38.8 %) had PAP III D findings. The spontaneous remission rate of untreated PAP III patients was 6 % and that of untreated PAP III D patients was 11 %. The remission rates of patients treated with a vaginal gel were 77 % for PAP III and 71 % for PAP III D.

Conclusion: A new treatment option was used in gynecological practice on patients with PAP III and PAP III D findings between confirmation and the next follow-up with excellent success.

Zusammenfassung

Einleitung: Die Diagnose und Therapie zervikaler zytologischer Zellveränderungen sind in europäischen und nationalen gynäkologischen Leitlinien abgebildet. Ziel dieser Datenerhebung war die Erfassung der Remissionsraten von PAP III- und PAP III D-Befunden in Beobachtungszeiträumen von 3–4 Monaten.

Methode: Im Rahmen einer retrospektiven Datensammlung sollte der derzeitige Stand des Managements suspekter und pathologischer zytologischer Befunde (PAP III und III D) in der gynäkologischen Praxis erfasst werden. Über einen Zeitraum von 24 Monaten wurden durchgeführte Präventionsmaßnahmen, Auftreten und Veränderung normaler/suspekter/pathologischer Befunde sowie das Therapiemanagement (bei suspektem oder pathologischem Befund) evaluiert.

Ergebnisse: 307 Patientinnen wurden in die Analyse eingeschlossen. Zum Zeitpunkt der Erhebung hatten 186 Patientinnen (60,6 %) einen PAP III- und 119 Patientinnen (38,8 %) einen PAP III D-Befund. Die spontane Remissionsrate der unbehandelten PAP III-Patientinnen lag bei 6 %, jene der unbehandelten PAP III D-Patientinnen bei 11 %. Die Remissionsraten der mit einem Vaginalgel behandelten Patientinnen betrugen 77 % (PAP III) beziehungsweise 71 % (PAP III D).

Schlussfolgerung: In der gynäkologischen Praxis wird zu einem hohen Prozentsatz eine neue Therapieoption bei Patientinnen mit PAP III- und PAP III D-Befunden während der Zeitintervalle zur nächsten Kontrolluntersuchung mit ausgezeichneten Erfolgen eingesetzt.

Key words

PAP III - PAP III D - cervix - gynaecology

Schlüsselwörter

PAP III - PAP III D - Zervix - Gynäkologie
 

  • References

  • 1 Leitlinien der ÖGZ zur Nomenklatur und zervixzytologischen Befundwiedergabe. Vorstandsbeschluss der ÖGZ vom 23.05.2005.
    Google Scholar
  • 2 Griesser H, Marquardt K, Jordan B et al. Münchner Nomenklatur III. Frauenarzt 2013; 54: 1042-1048
    Google Scholar
  • 3 Apgar BS, Zoschnick L, Wright TC. The 2001 Bethesda System terminology. Am Fam Physician 2003; 68: 1992-1998
    Google Scholar
  • 4 Breitenecker G, Girardi F, Joura EA et al. Leitlinie für die Diagnose und Therapie von Cervicalen Intraepithelialen Neoplasien (CIN) und Mikrokarzinom der Cervix uteri. Speculum 2005; 23: 20-25
    Google Scholar
  • 5 Castellsagué X, Bosch FX, Muñoz N. Environmental co-factors in HPV carcinogenesis. Virus Res 2002; 89: 191-199
    CrossrefGoogle Scholar
  • 6 Castle PE, Giuliano AR. Chapter 4: Genital tract infections, cervical inflammation, and antioxidant nutrients—assessing their roles as human papillomavirus cofactors. J Natl Cancer Inst Monogr 2003; (31) 29-34
    Google Scholar
  • 7 Ideström M, Milsom I, Andersson-Ellström A. Womenʼs experience of coping with a positive Pap smear: A register-based study of women with two consecutive Pap smears reported as CIN 1. Acta Obstet Gynecol Scand 2003; 82: 756-761
    CrossrefGoogle Scholar
  • 8 Lee Mortensen G, Adeler AL. Qualitative study of womenʼs anxiety and information needs after a diagnosis of cervical dysplasia. Z Gesundh Wiss 2010; 18: 473-482
    CrossrefGoogle Scholar
  • 9 Monsonego J, Cortes J, da Silva DP et al. Psychological impact, support and information needs for women with an abnormal Pap smear: comparative results of a questionnaire in three European countries. BMC Womens Health 2011; 11: 18
    CrossrefGoogle Scholar
  • 10 Gray NM, Sharp L, Cotton SC et al. Psychological effects of a low-grade abnormal cervical smear test result: anxiety and associated factors. Br J Cancer 2006; 94: 1253-1262
    CrossrefGoogle Scholar
  • 11 Jones MH, Singer A, Jenkins D. The mildly abnormal cervical smear: patient anxiety and choice of management. J R Soc Med 1996; 89: 257-260
    Google Scholar
  • 12 Hillemanns P, Thaler C, Kimmig R. Epidemiologie und Diagnostik der zervikalen intraepithelialen Neoplasie – Ist das derzeitige Konzept von Screening und Diagnostik noch aktuell?. Gynäkol Geburtshilfliche Rundsch 1997; 37: 179-190
    CrossrefGoogle Scholar
  • 13 Nasiell K, Nasiell M, Vaćlavinková V. Behavior of moderate cervical dysplasia during long-term follow-up. Obstet Gynecol 1983; 61: 609-614
    Google Scholar
  • 14 Iwasaka T, Hayashi Y, Yokoyama M et al. Interferon gamma treatment for cervical intraepithelial neoplasia. Gynecol Oncol 1990; 37: 96-102
    CrossrefGoogle Scholar
  • 15 R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; ISBN 3-900051-07-0. Online: http://www.r-project.org last access: 03.03.2016
    Google Scholar
  • 16 Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55
    CrossrefGoogle Scholar
  • 17 Pearl J. Understanding propensity scores. Causality: models, reasoning, and inference. Cambridge, United Kingdom: Cambridge University Press; 2009
    CrossrefGoogle Scholar
  • 18 Chambers JM. Chapter 4 of statistical Models in S. In: Chambers JM, Hastie TJ, eds. Linear Models. Pacific Grove, California, USA: Wadsworth & Brooks/Cole; 1992
    Google Scholar
  • 19 Ferrante JM, Mayhew DY, Goldberg S et al. Empiric treatment of minimally abnormal papanicolaou smears with 0.75 % metronidazole vaginal gel. J Am Board Fam Pract 2002; 15: 347-354
    Google Scholar
  • 20 Connor JP, Elam G, Goldberg JM. Empiric vaginal metronidazole in the management of the ASCUS Papanicolaou smear: a randomized controlled trial. Obstet Gynecol 2002; 99: 183-187
    Google Scholar
  • 21 Marais D, Carrara H, Kay P et al. The impact of the use of COL-1492, a nonoxynol-9 vaginal gel, on the presence of cervical human papillomavirus in female sex workers. Virus Res 2006; 121: 220-222
    CrossrefGoogle Scholar
  • 22 Holmes MM, Weaver 2nd SH, Vermillion ST. A randomized, double-blind, placebo-controlled trial of 5-fluorouracil for the treatment of cervicovaginal human papillomavirus. Infect Dis Obstet Gynecol 1999; 7: 186-189
    CrossrefGoogle Scholar
  • 23 Sikorski M, Zrubek H. Recombinant human interferon gamma in the treatment of cervical intraepithelial neoplasia (CIN) associated with human papillomavirus (HPV) infection. Eur J Gynecol Oncol 2003; 24: 147-150
    Google Scholar
  • 24 Frost L, Skajaa K, Hvidman LE et al. No effect of intralesional injection of interferon on moderate cervical intraepithelial neoplasia. Br J Obstet Gynaecol 1990; 97: 626-630
    CrossrefGoogle Scholar
  • 25 Kurzeja R, Böhmer G, Schneider A. Clinical outcome of topical interferon alpha-2b cream in phase II trial for LSIL/CIN 1 patients. J Cancer Ther 2011; 2: 203-208
    CrossrefGoogle Scholar
  • 26 Fox PA, Nathan M, Francis N et al. A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod. AIDS 2010; 24: 2331-2335
    Google Scholar
  • 27 van Seters M, van Beurden M, ten Kate FJ et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 2008; 358: 1465-1473
    CrossrefPubMedGoogle Scholar
  • 28 van Egmond S, Hoedemaker C, Sinclair R. Successful treatment of perianal Bowenʼs disease with imiquimod. Int J Dermatol 2007; 46: 318-319
    CrossrefGoogle Scholar
  • 29 Mahto M, Nathan M, OʼMahony C. More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia. Int J STD AIDS 2010; 21: 8-16
    CrossrefGoogle Scholar
  • 30 Grimm C, Polterauer S, Natter C et al. Treatment of cervical intraepithelial neoplasia with topical imiquimod. Obstet Gynecol 2012; 120: 152-159
    CrossrefGoogle Scholar